FDA 483 - Shire Human Genetic Therapies Inc - September 12, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Shire Human Genetic Therapies, Inc. in Cambridge, MA, revealed multiple deficiencies in aseptic manufacturing and quality control. The firm failed to follow procedures to prevent microbiological contamination, had inadequate airflow visualization studies, and lacked comprehensive disinfectant efficacy testing. Additionally, the quality control unit did not periodically evaluate electronic audit trail data, and equipment was not cleaned properly, indicating significant risks to drug substance quality and purity.
ID · 6129a655-a3aa-44c0-8fc8-c61794d4a83a